摘要
目的:研究与分析瑞舒伐他汀对慢性阻塞性肺疾病合并肺心病患者炎性因子及免疫功能的影响。方法:选取2015年1月-2017年1月本院收治的慢性阻塞性肺疾病合并肺心病患者80例,将其随机分为观察组与对照组,各40例。对照组采取常规内科治疗,观察组在对照组基础上采用瑞舒伐他汀治疗。比较两组治疗前后炎性细胞因子如超敏C反应蛋白(hs-CRP)、白细胞介素1(IL-1)、肿瘤坏死因子-α(TNF-α)以及免疫球蛋白IgA、IgG、IgM等指标变化。结果:治疗前,两组hs-CRP、IL-1、TNF-α、IgA、IgG、IgM比较,差异均无统计学意义(P>0.05)。治疗后,观察组hs-CRP、IL-1、TNF-α均显著低于对照组,差异均有统计学意义(P<0.05);而观察组的IgA、IgG、IgM均显著高于对照组,差异均有统计学意义(P<0.05)。结论:瑞舒伐他汀治疗慢性阻塞性肺疾病合并肺心病患者的效果显著,能有效增强其机体免疫功能,减轻其炎性反应,值得应用推广。
Objective:To study and analyze the effect of Rosuvastatin on chronic obstructive pulmonary disease complicated with pulmonary heart disease in patients with inflammatory factors and immune function.Method:80 patients in our hospital from January 2015 to January 2017 were chronic obstructive pulmonary disease complicated with pulmonary heart disease,which are randomly divided into observation group and control group,each of 40 cases.The control group took routine treatment,the observation group was treated with Rosuvastatin on the basis of the control group.The changes of inflammatory cytokines such as hypersensitivity C reactive protein(hs-CRP),interleukin 1(IL-1),tumor necrosis factor alpha(TNF-α)and immunoglobulin IgA,IgG and IgM were compared between the two groups before and after treatment.Result:Before treatment,there were no significant differences between the two groups of hs-CRP,IL-1,TNF-α,IgA,IgG,IgM(P>0.05).After treatment,the hs-CRP,IL-1,TNF-αin the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05);the IgA,IgG and IgM of the observation group were significantly higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Rosuvastatin treatment in patients with chronic obstructive pulmonary disease complicated with pulmonary heart disease has significant effect,which can effectively enhance the body Immune function,reduce its inflammatory response,it is worth popularizing.
作者
丘韶校
李元广
何臣
徐效峰
QIU Shaoxiao;LI Yuanguang;HE Chen(The People’s Hospital in Bao’an District of Shenzhen City,Shenzhen 518100,China)
出处
《中国医学创新》
CAS
2017年第36期128-131,共4页
Medical Innovation of China
关键词
瑞舒伐他汀
慢性阻塞性肺疾病
肺心病
炎性因子
免疫功能
Rosuvastatin
Chronic obstructive pulmonary disease
Cor pulmonale
Inflammatory factors
Immune function
